EUS-RFA PANCARDINAL-1 Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją rak trzustki.
- •Posiadanie stałego adresu zamieszkania w Polsce.
- •Wyrażenie zgody na udział w badaniu.
- •Badanie TK potwierdzające raka trzustki.
- •Brak wcześniejszej chemioterapii lub mniej niż 2 miesiące przedoperacyjnej chemioterapii.
✗ Disqualifies
- •Osoby poniżej 18. roku życia.
- •Brak stałego adresu zamieszkania lub numeru telefonu.
- •Ciąża.
- •Pacjenci przebywający w zakładach karnych.
- •Brak możliwości udzielenia świadomej zgody.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Memorial Hermann Hospital
Houston, United States
Trial contact
Amatullah Alibhai, B.A., M.B.A.
Nicole Fatheree, B.B.A.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.